Protara Therapeutics Inc is trading 5.1% up at $4.00 after investors reacted to shareholder approval to increase the company's authorized common stock from 100 million to 200 million shares.
- The proposal, passed at the June 12 annual meeting, has fueled speculation regarding potential future capital-raising or strategic corporate activities.
- The stock continues to see positive momentum following a pre-market jump originally reported on June 16.